| Literature DB >> 31470687 |
Zhixing Ren1, Yingwei Wang2, Haihong Xu3, Yufei Li1, Song Han1.
Abstract
Most studies on adverse drug reactions (ADRs) of fluoroquinolones (FQs) have focused on the mechanisms of single ADRs, and no quantitative structure-activity relationship (QSAR) method studies have been carried out that combine several ADRs of FQs. In this study, an improved three-dimensional (3D) QSAR method was established using fuzzy comprehensive evaluation. This method could simultaneously consider three common ADRs of FQs using molecular parameters. The improved method could comprehensively predict three ADRs of FQs and provide direction for the development of new drugs with lower ADRs than the originals. According to the improved method, 48 derivatives with lower ADRs (decreased by 4.86% to 50.92%) were designed from pazufloxacin. Three derivatives with a higher genotoxicity, higher photodegradation, and lower bioconcentration than pazufloxacin were selected using the constructed QSAR methods of the FQs. Finally, three traditional 3D-QSAR methods of single ADR were constructed to validate the improved method. The improved method was reasonable, with a relative error range of 0.96% to 4.30%. This study provides valuable reference data and will be useful for the development of strategies to produce new drugs with few ADRs. In the absence of complementary biological studies of these adverse drug reactions, the results reported here may be quite divergent from those found in humans or experimental animals in vivo. One major reason for this is that many adverse drug reactions are dependent upon enzyme-catalyzed metabolic activation (toxication) or on non-enzymatic conversion to toxic products and are not due to the parent drug moiety.Entities:
Keywords: 3D-QSAR method; ADRs; fuzzy comprehensive evaluation
Mesh:
Substances:
Year: 2019 PMID: 31470687 PMCID: PMC6747076 DOI: 10.3390/ijerph16173161
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Maternal structure of fluoroquinolones (FQs). R1 is a hydrocarbon group usually, R2 is usually a piperazine ring, X is carbon or nitrogen.
Figure 2Mechanism of fluoroquinolone action in bacterial cells.
Figure 3Workflow chart.
Figure 4Selecting the target compound to align with the common framework.
Figure 5The result of all the molecules overlapping.
Docking and comprehensive evaluation of 29 fluoroquinolones (FQs)with three adverse drug reactions.
| No. | Compounds | Docking Results | CEI | ||
|---|---|---|---|---|---|
| 3IP9 | 3N8V | 2L0W | |||
| 1 | Difloxacin | 62.686 | 97.120 | 65.403 | 0.687 |
| 2 | Enrofloxacin | 64.070 | 90.401 | 90.476 | 0.707 |
| 3 | Norfloxacin | 58.422 | 90.557 | 88.709 | 0.601 |
| 4 | Lomefloxacin | 68.236 | 91.137 | 80.276 | 0.762 |
| 5 | Ofloxacin | 66.638 | 86.122 | 86.940 | 0.697 |
| 6 | Pefloxacin | 57.529 | 99.215 | 92.037 | 0.689 |
| 7 | Fleroxacin | 66.948 | 99.890 | 83.403 | 0.843 |
| 8 | Ciprofloxacin | 60.930 | 92.373 | 86.780 | 0.661 |
| 9 | Bal ofloxacin | 49.203 | 71.254 | 56.908 | 0.137 |
| 10 | Marbofloxacin | 65.300 | 95.242 | 88.670 | 0.777 |
| 11 | Pipemidic acid | 62.866 | 97.025 | 89.229 | 0.754 |
| 12 | Cinoxacin | 55.950 | 90.199 | 85.239 | 0.543 |
| 13 | Enoxacin | 60.660 | 86.605 | 87.601 | 0.596 |
| 14 | Danofloxacin | 67.775 | 91.772 | 93.715 | 0.797 |
| 15 | Gatifloxacin | 53.617 | 63.247 | 64.941 | 0.152 |
| 16 | Levofloxacin | 66.638 | 86.122 | 86.940 | 0.697 |
| 17 | Rufloxacin | 62.386 | 70.009 | 76.275 | 0.415 |
| 18 | Pazufloxacin | 74.075 | 94.849 | 86.206 | 0.925 |
| 19 | Nadifloxacin | 56.928 | 82.392 | 73.634 | 0.444 |
| 20 | Moxifloxacin | 46.442 | 73.108 | 73.101 | 0.152 |
| 21 | Sparfloxacin | 60.872 | 84.400 | 85.512 | 0.570 |
| 22 | Sarafloxacin | 59.595 | 82.206 | 72.443 | 0.487 |
| 23 | Amifloxacin | 59.512 | 86.682 | 80.072 | 0.555 |
| 24 | Besifloxacin | 55.541 | 79.981 | 76.735 | 0.401 |
| 25 | Clinafloxacin | 59.317 | 86.327 | 80.656 | 0.549 |
| 26 | Grepafloxacin | 66.245 | 90.285 | 93.474 | 0.753 |
| 27 | Orbifloxacin | 62.945 | 81.585 | 84.843 | 0.575 |
| 28 | Sitafloxacin | 60.702 | 72.267 | 83.135 | 0.428 |
| 29 | Temafloxacin | 66.934 | 88.733 | 75.241 | 0.699 |
Evaluation parameters of the comparative molecular field analysis (CoMFA) models.
| Model |
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| CoMFA | 0.560 | 10 | 0.007 | 0.999 | 1892.254 | 0.215 | 0.999 | 0.246 | 1.861 | 0.692 |
SEP: standard error of prediction; cSDEP: cross-validated standard error of prediction.
Figure 6Correlation between experimental values and predicted values of CEI in the CoMFA model.
Experimental and predicted values of fluoroquinolones through the CoMFA model.
| No. | Compounds | CEI | Pred. | Residuals |
|---|---|---|---|---|
| 1 | Difloxacinb | 0.687 | 0.688 | 0.18% |
| 2 | Enrofloxacina | 0.707 | 0.706 | 0.08% |
| 3 | Norfloxacina | 0.601 | 0.618 | 2.78% |
| 4 | Lomefloxacina | 0.762 | 0.756 | 0.82% |
| 5 | Ofloxacina | 0.697 | 0.702 | 0.76% |
| 6 | Pefloxacina | 0.689 | 0.686 | 0.39% |
| 7 | Fleroxacina | 0.843 | 0.846 | 0.35% |
| 8 | Ciprofloxacina | 0.661 | 0.663 | 0.26% |
| 9 | Balofloxacina | 0.137 | 0.140 | 1.92% |
| 10 | Marbofloxacina | 0.777 | 0.782 | 0.67% |
| 11 | Pipemidic acida | 0.754 | 0.751 | 0.36% |
| 12 | Cinoxacina | 0.543 | 0.542 | 0.23% |
| 13 | Enoxacina | 0.596 | 0.587 | 1.45% |
| 14 | Danofloxacina | 0.797 | 0.794 | 0.42% |
| 15 | Gatifloxacina | 0.152 | 0.149 | 1.74% |
| 16 | Levofloxacina | 0.697 | 0.700 | 0.47% |
| 17 | Rufloxacina | 0.415 | 0.417 | 0.50% |
| 18 | Pazufloxacina b | 0.925 | 0.922 | 0.28% |
| 19 | Nadifloxacina | 0.444 | 0.442 | 0.49% |
| 20 | Moxifloxacina | 0.152 | 0.152 | 0.23% |
| 21 | Sparfloxacina | 0.570 | 0.568 | 0.30% |
| 22 | Sarafloxacinb | 0.487 | 0.471 | 3.31% |
| 23 | Amifloxacinb | 0.555 | 0.554 | 0.22% |
| 24 | Besifloxacina | 0.401 | 0.327 | 18.49% |
| 25 | Clinafloxacinb | 0.549 | 0.415 | 24.47% |
| 26 | Grepafloxacinb | 0.753 | 0.544 | 27.74% |
| 27 | Orbifloxacina | 0.575 | 0.570 | 0.82% |
| 28 | Sitafloxacinb | 0.428 | 0.462 | 8.01% |
| 29 | Temafloxacinb | 0.699 | 0.676 | 3.26% |
a Training set; b Test set.
Figure 7Contour maps of the CoMFA model, steric fields (a); electrostatic fields (b).
Prediction of CEI index of derivatives based on CoMFA models.
| Compounds | Structure | CEI | |
|---|---|---|---|
| Pred. | Relative Error | ||
| No.18 | PAZ | 0.925 | - |
| Derivative-1 | 1-Methyl-PAZ | 0.619 | −33.08% |
| Derivative-2 | 1-Hydrogen-PAZ | 0.578 | −37.51% |
| Derivative-3 | 1-Ethyl-PAZ | 0.649 | −29.84% |
| Derivative-4 | 1-Vinyl-PAZ | 0.660 | −28.65% |
| Derivative-5 | 1-Ethynyl-PAZ | 0.719 | −22.27% |
| Derivative-6 | 1-Carbonyl-PAZ | 0.792 | −14.38% |
| Derivative-7 | 5-Hydroxyl-PAZ | 0.879 | −4.97% |
| Derivative-8 | 5-Carboxyl-PAZ | 0.827 | −10.59% |
| Derivative-9 | 5-Sulfur-PAZ | 0.848 | −8.32% |
| Derivative-10 | 5-Fluorine-PAZ | 0.814 | −12.00% |
| Derivative-11 | 5-Chlorine-PAZ | 0.717 | −22.49% |
| Derivative-12 | 5-Bromine-PAZ | 0.726 | −21.51% |
| Derivative-13 | 1-Methyl-5-Hydroxyl-PAZ | 0.762 | −17.62% |
| Derivative-14 | 1-Methyl-5-Carboxyl-PAZ | 0.743 | −19.68% |
| Derivative-15 | 1-Methyl-5-Sulfur-PAZ | 0.778 | −15.89% |
| Derivative-16 | 1-Methyl-5-Fluorine-PAZ | 0.715 | −22.70% |
| Derivative-17 | 1-Methyl-Chlorine-PAZ | 0.743 | −19.68% |
| Derivative-18 | 1-Methyl-5-Bromine-PAZ | 0.775 | −16.22% |
| Derivative-19 | 1-Hydrogen-5-Hydroxyl-PAZ | 0.652 | −29.51% |
| Derivative-20 | 1-Hydrogen-5-Carboxyl-PAZ | 0.592 | −36.00% |
| Derivative-21 | 1-Hydrogen-5-Sulfur-PAZ | 0.641 | −30.70% |
| Derivative-22 | 1-Hydrogen-5-Fluorine-PAZ | 0.549 | −40.65% |
| Derivative-23 | 1-Hydrogen-Chlorine-PAZ | 0.637 | −31.14% |
| Derivative-24 | 1-Hydrogen-5-Bromine-PAZ | 0.659 | −28.76% |
| Derivative-25 | 1-Ethyl-5-Hydroxyl-PAZ | 0.754 | −18.49% |
| Derivative-26 | 1-Ethyl-5-Carboxyl-PAZ | 0.796 | −13.95% |
| Derivative-27 | 1-Ethyl-5-Sulfur-PAZ | 0.776 | −16.11% |
| Derivative-28 | 1-Ethyl-5-Fluorine-PAZ | 0.727 | −21.41% |
| Derivative-29 | 1-Ethyl-Chlorine-PAZ | 0.828 | −10.49% |
| Derivative-30 | 1-Ethyl-5-Bromine-PAZ | 0.732 | −20.86% |
| Derivative-31 | 1-Vinyl-5-Hydroxyl-PAZ | 0.677 | −26.81% |
| Derivative-32 | 1-Vinyl-5-Carboxyl-PAZ | 0.613 | −33.73% |
| Derivative-33 | 1-Vinyl-5-Sulfur-PAZ | 0.710 | −23.24% |
| Derivative-34 | 1-Vinyl-5-Fluorine-PAZ | 0.691 | −25.30% |
| Derivative-35 | 1-Vinyl-5-Chlorine-PAZ | 0.558 | −39.68% |
| Derivative-36 | 1-Vinyl-5-Bromine-PAZ | 0.454 | −50.92% |
| Derivative-37 | 1-Ethynyl-5-Hydroxyl-PAZ | 0.659 | −28.76% |
| Derivative-38 | 1-Ethynyl-5-Carboxyl-PAZ | 0.880 | −4.86% |
| Derivative-39 | 1-Ethynyl-5-Sulfur-PAZ | 0.875 | −5.41% |
| Derivative-40 | 1-Ethynyl-5-Fluorine-PAZ | 0.742 | −19.78% |
| Derivative-41 | 1- Ethynyl-5-Chlorine-PAZ | 0.800 | −13.51% |
| Derivative-42 | 1-Ethynyl-5-Bromine-PAZ | 0.636 | −31.24% |
| Derivative-43 | 1-Carbonyl-5-Hydroxyl-PAZ | 0.718 | −22.38% |
| Derivative-44 | 1-Carbonyl-5-Carboxyl-PAZ | 0.682 | −26.27% |
| Derivative-45 | 1-Carbonyl-5-Sulfur-PAZ | 0.574 | −37.95% |
| Derivative-46 | 1-Carbonyl-5-Fluorine-PAZ | 0.600 | −35.14% |
| Derivative-47 | 1-Carbonyl-5-Chlorine-PAZ | 0.758 | −18.05% |
| Derivative-48 | 1-Carbonyl-5-Bromine-PAZ | 0.633 | −31.57% |
Evaluation of POPs characteristics of PAZ derivatives based on constructed QSAR.
| Compounds | pLOEC (Pred. AVG) * | log | log | |||
|---|---|---|---|---|---|---|
| Pred. | Relative Error | Pred. | Relative Error | Pred. | Relative Error | |
| PAZ | 7.048 | - | 1.789 | - | 1.140 | - |
| Derivative-1 | 7.404 | 5.05% | 1.925 | 7.60% | 0.191 | −83.25% |
| Derivative-2 | 7.575 | 7.48% | 1.954 | 9.22% | 0.140 | −87.72% |
| Derivative-3 | 7.322 | 3.89% | 1.937 | 8.27% | 0.289 | −74.65% |
| Derivative-4 | 6.930 | −1.67% | 1.934 | 8.11% | 1.689 | 48.16% |
| Derivative-5 | 6.936 | −1.59% | 1.869 | 4.47% | 1.602 | 40.53% |
| Derivative-6 | 6.777 | −3.85% | 1.926 | 7.66% | 1.254 | 10.00% |
| Derivative-7 | 7.082 | 0.48% | 1.726 | −3.52% | 1.169 | 2.54% |
| Derivative-8 | 7.203 | 2.20% | 1.821 | 1.79% | 1.631 | 43.07% |
| Derivative-9 | 7.073 | 0.35% | 1.728 | −3.41% | 1.354 | 18.77% |
| Derivative-10 | 7.089 | 0.58% | 1.744 | −2.52% | 1.113 | −2.37% |
| Derivative-11 | 7.031 | −0.24% | 1.732 | −3.19% | 1.170 | 2.63% |
| Derivative-12 | 7.033 | −0.21% | 1.954 | 9.22% | 1.126 | −1.23% |
| Derivative-13 | 7.022 | −0.37% | 1.827 | 2.12% | 1.856 | 62.81% |
| Derivative-14 | 7.009 | −0.55% | 1.555 | −13.08% | 2.623 | 130.09% |
| Derivative-15 | 7.048 | 0.00% | 1.987 | 11.07% | 2.083 | 82.72% |
| Derivative-16 | 7.061 | 0.18% | 1.831 | 2.35% | 1.848 | 62.11% |
| Derivative-17 | 6.993 | −0.78% | 1.930 | 7.88% | 1.907 | 67.28% |
| Derivative-18 | 7.007 | −0.58% | 1.862 | 4.08% | 2.102 | 84.39% |
| Derivative-19 | 7.193 | 2.06% | 1.860 | 3.97% | 1.629 | 42.89% |
| Derivative-20 | 7.245 | 2.80% | 1.942 | 8.55% | 2.108 | 84.91% |
| Derivative-21 | 7.185 | 1.94% | 1.862 | 4.08% | 1.794 | 57.37% |
| Derivative-22 | 7.129 | 1.15% | 1.952 | 9.11% | 1.768 | 55.09% |
| Derivative-23 | 7.121 | 1.04% | 1.969 | 10.06% | 1.545 | 35.53% |
| Derivative-24 | 7.173 | 1.77% | 1.877 | 4.92% | 1.639 | 43.77% |
| Derivative-25 | 7.030 | −0.26% | 2.028 | 13.36% | 2.055 | 80.26% |
| Derivative-26 | 7.034 | −0.20% | 2.073 | 15.87% | 2.254 | 97.72% |
| Derivative-27 | 7.051 | 0.04% | 1.978 | 10.56% | 2.087 | 83.07% |
| Derivative-28 | 7.033 | −0.21% | 1.837 | 2.68% | 1.875 | 64.47% |
| Derivative-29 | 6.988 | −0.85% | 1.956 | 9.33% | 2.085 | 82.89% |
| Derivative-30 | 7.055 | 0.10% | 1.847 | 3.24% | 1.917 | 68.16% |
| Derivative-31 | 6.987 | −0.87% | 1.903 | 6.37% | 2.317 | 103.25% |
| Derivative-32 | 6.938 | −1.56% | 1.414 | −20.96% | 2.378 | 108.60% |
| Derivative-33 | 6.743 | −4.33% | 1.769 | −1.12% | 2.599 | 127.98% |
| Derivative-34 | 7.253 | 2.91% | 1.438 | −19.62% | 0.486 | −57.37% |
| Derivative-35 | 7.242 | 2.75% | 1.941 | 8.50% | 2.403 | 110.79% |
| Derivative-36 | 7.293 | 3.48% | 1.939 | 8.38% | 2.330 | 104.39% |
| Derivative-37 | 7.123 | 1.06% | 1.884 | 5.31% | 2.205 | 93.42% |
| Derivative-38 | 6.949 | −1.40% | 1.709 | −4.47% | 2.515 | 120.61% |
| Derivative-39 | 6.922 | −1.79% | 2.060 | 15.15% | 2.352 | 106.32% |
| Derivative-40 | 6.884 | −2.33% | 1.749 | −2.24% | 2.215 | 94.30% |
| Derivative-41 | 7.056 | 0.11% | 1.854 | 3.63% | 1.959 | 71.84% |
| Derivative-42 | 7.076 | 0.40% | 1.942 | 8.55% | 2.184 | 91.58% |
| Derivative-43 | 7.180 | 1.87% | 1.880 | 5.09% | 1.580 | 38.60% |
| Derivative-44 | 7.057 | 0.13% | 1.870 | 4.53% | 1.960 | 71.93% |
| Derivative-45 | 7.149 | 1.43% | 1.864 | 4.19% | 1.535 | 34.65% |
| Derivative-46 | 7.155 | 1.52% | 1.953 | 9.17% | 1.614 | 41.58% |
| Derivative-47 | 6.953 | −1.35% | 1.767 | −1.23% | 1.919 | 68.33% |
| Derivative-48 | 7.152 | 1.48% | 1.921 | 7.38% | 1.669 | 46.40% |
* H-QSAR model chosen Pred. AVG as the final prediction value.
Contrastive validation of single-factor and multi-factor adverse drug reactions of FQs derivatives.
| Evaluation Project | PAZ | Derivative-1 | Derivative-2 | Derivative-3 |
|---|---|---|---|---|
| Comprehensive evaluation index | 0.925 | 0.619 | 0.578 | 0.649 |
| −33.08% | −37.51% | −29.84% | ||
| Convulsive Toxicity | 74.075 | 62.218 | 60.048 | 63.499 |
| −16.01% | −18.94% | −14.28% | ||
| CEI × 50% | - | −16.54% | −18.76% | −14.92% |
| Relative error | 3.23% | 0.96% | 4.30% | |
| Gastrointestinal Toxicity | 99.890 | 87.029 | 85.286 | 88.230 |
| −12.88% | −14.62% | −11.67% | ||
| CEI × 40% | - | −13.23% | −15.01% | −11.94% |
| Relative error | 2.70% | 2.57% | 2.20% | |
| Cardiotoxicity | 93.715 | 91.282 | 91.352 | 91.266 |
| −2.60% | −2.52% | −2.61% | ||
| CEI × 10% | - | −3.31% | −3.75% | −2.98% |
| Relative error | 15.07% | 32.78% | 12.42% |
Figure 8The substitution reaction paths of PAZ.
PAZ derivatives’ three substitution reaction paths, positive frequency, Gibbs free energy, and energy barrier calculation.
| Compounds | Frequency/(cm−1) | ΔG/(a.u.) | ΔE/(a.u.) |
|---|---|---|---|
| Path 1 (–CH3) | 35.02 | −0.026 | 39.307 |
| Path 2 (–H) | 39.97 | −0.023 | 39.439 |
| Path 3 (–C2H5) | 35.60 | −0.023 | 40.617 |
Exposure dose (ADD), Non-carcinogenic risk index (HI), and Lifetime cancer risk index (RI) evaluation results of three PAZ derivatives.
| Molecule | Medium | Carcinogenicity | Fish | Water Fleas | Shrimp | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |||
| Derivative-1 | sensitive | Carcinogenic | 0.0002 | 0.0117 | 2.81 × 10−5 | 0.0001 | 0.0055 | 1.32 × 10−5 | 4.36 × 10−5 | 0.0022 | 5.23 × 10−6 |
| Non-Carcinogenic | 8.03 × 10−5 | 0.0040 | 9.64 × 10−6 | 3.77 × 10−5 | 0.0019 | 4.53 × 10−6 | 1.49 × 10−5 | 0.0007 | 1.79 × 10−6 | ||
| Non-sensitive | Carcinogenic | 9.41 × 10−5 | 0.0047 | 1.13 × 10−5 | 4.42 × 10−5 | 0.0022 | 5.30 × 10−6 | 1.75 × 10−5 | 0.0009 | 2.10 × 10−6 | |
| Non-Carcinogenic | 3.36 × 10−5 | 0.0017 | 4.03 × 10−6 | 1.58 × 10−5 | 0.0008 | 1.89 × 10−6 | 6.25 × 10−6 | 0.0003 | 7.50 × 10−7 | ||
| Derivative-2 | sensitive | Carcinogenic | 0.0005 | 0.0248 | 5.94 × 10−5 | 0.0003 | 0.0134 | 3.21 × 10−5 | 0.0001 | 0.0067 | 1.60 × 10−5 |
| Non-Carcinogenic | 0.0002 | 0.0085 | 2.04 × 10−5 | 9.19 × 10−5 | 0.0046 | 1.10 × 10−5 | 4.58 × 10−5 | 0.0023 | 5.50 × 10−6 | ||
| Non-sensitive | Carcinogenic | 0.0002 | 0.0100 | 2.39 × 10−5 | 0.0001 | 0.0054 | 1.29 × 10−5 | 5.37 × 10−5 | 0.0027 | 6.44 × 10−6 | |
| Non-Carcinogenic | 7.11 × 10−5 | 0.0036 | 8.53 × 10−6 | 3.85 × 10−5 | 0.0019 | 4.61 × 10−6 | 1.92 × 10−5 | 0.0010 | 2.30 × 10−6 | ||
| Derivative-3 | sensitive | Carcinogenic | 0.0001 | 0.0052 | 1.21 × 10−5 | 4.17 × 10−5 | 0.0021 | 5.00 × 10−6 | 1.29 × 10−5 | 0.0006 | 1.55 × 10−6 |
| Non-Carcinogenic | 3.55 × 10−5 | 0.0018 | 4.26 × 10−6 | 1.43 × 10−5 | 0.0007 | 1.72 × 10−6 | 4.41 × 10−6 | 0.0002 | 5.30 × 10−7 | ||
| Non-sensitive | Carcinogenic | 4.16 × 10−5 | 0.0021 | 4.99 × 10−6 | 1.68 × 10−5 | 0.0008 | 2.01 × 10−6 | 5.17 × 10−6 | 0.0003 | 6.21 × 10−7 | |
| Non-Carcinogenic | 1.48 × 10−5 | 0.0007 | 1.78 × 10−6 | 5.98 × 10−6 | 0.0003 | 7.18 × 10−7 | 1.85 × 10−6 | 9.24 × 10−5 | 2.22 × 10−7 | ||
Figure 9Conversion path of disinfection by-products of PAZ derivatives.
Risk assessment of genotoxicity of disinfection by-products of PAZ.
| Compounds | Pred.59 | Relative Error | Pred.61 | Relative Error | Pred. AVG * | Relative Error |
|---|---|---|---|---|---|---|
| PAZ | 7.048 | |||||
| PAZ-Cl-1 | 7.448 | 5.68% | 7.992 | 13.39% | 7.720 | 9.53% |
| PAZ-Cl-2 | 7.719 | 9.52% | 8.113 | 15.11% | 7.916 | 12.32% |
| PAZ-Cl-3 | 7.806 | 10.75% | 7.991 | 13.38% | 7.899 | 12.07% |
| PAZ-Cl-4 | 7.588 | 7.66% | 8.195 | 16.27% | 7.891 | 11.96% |
| PAZ-Cl-5 | 7.378 | 4.68% | 7.755 | 10.03% | 7.567 | 7.36% |
| PAZ-Cl-6 | 7.275 | 3.22% | 7.678 | 8.94% | 7.477 | 6.09% |
| PAZ-Cl-7 | 7.149 | 1.43% | 7.533 | 6.88% | 7.341 | 4.16% |
| PAZ-Cl-8 | 6.967 | −1.15% | 7.235 | 2.65% | 7.101 | 0.75% |
| PAZ-Cl-9 | 6.829 | −3.11% | 7.355 | 4.36% | 7.092 | 0.62% |
| PAZ-Cl-10 | 7.497 | 6.37% | 7.709 | 9.38% | 7.603 | 7.87% |
| PAZ-Cl-11 | 7.481 | 6.14% | 7.670 | 8.83% | 7.575 | 7.48% |
| PAZ-Cl-12 | 7.415 | 5.21% | 7.649 | 8.53% | 7.532 | 6.87% |
| PAZ-Cl-13 | 7.375 | 4.64% | 7.572 | 7.43% | 7.473 | 6.03% |
* H-QSAR model chosen Pred. AVG as the final prediction value.
Risk assessment of genotoxicity of disinfection by-products of PAZ derivatives.
| Compounds | Pred.59 | Relative Error | Pred.61 | Relative Error | Pred. AVG * | Relative Error |
|---|---|---|---|---|---|---|
| Derivative-1 | 7.404 | |||||
| Derivative-1-Cl-1 | 7.335 | −0.93% | 7.907 | 6.79% | 7.621 | 2.93% |
| Derivative-1-Cl-2 | 7.439 | 0.47% | 7.745 | 4.61% | 7.592 | 2.54% |
| Derivative-1-Cl-3 | 7.523 | 1.61% | 7.615 | 2.85% | 7.569 | 2.23% |
| Derivative-1-Cl-4 | 7.162 | −3.27% | 7.466 | 0.84% | 7.314 | −1.22% |
| Derivative-1-Cl-5 | 6.506 | −12.13% | 6.524 | −11.89% | 6.515 | −12.01% |
| Derivative-1-Cl-6 | 6.815 | −7.96% | 7.227 | −2.39% | 7.021 | −5.17% |
| Derivative-1-Cl-7 | 6.823 | −7.85% | 7.200 | −2.76% | 7.011 | −5.31% |
| Derivative-1-Cl-8 | 7.125 | −3.77% | 7.181 | −3.01% | 7.153 | −3.39% |
| Derivative-1-Cl-9 | 7.076 | −4.43% | 7.119 | −3.85% | 7.097 | −4.15% |
| Derivative-1-Cl-10 | 7.012 | −5.29% | 7.100 | −4.11% | 7.056 | −4.70% |
| Derivative-1-Cl-11 | 7.027 | −5.09% | 7.024 | −5.13% | 7.025 | −5.12% |
| Derivative-2 | 7.575 | |||||
| Derivative-2-Cl-1 | 7.049 | −6.94% | 7.399 | −2.32% | 7.224 | −4.63% |
| Derivative-2-Cl-2 | 7.145 | −5.68% | 7.293 | −3.72% | 7.219 | −4.70% |
| Derivative-2-Cl-3 | 7.246 | −4.34% | 7.167 | −5.39% | 7.207 | −4.86% |
| Derivative-2-Cl-4 | 6.506 | −14.11% | 6.524 | −13.87% | 6.515 | −13.99% |
| Derivative-2-Cl-5 | 6.815 | −10.03% | 7.227 | −4.59% | 7.021 | −7.31% |
| Derivative-2-Cl-6 | 6.823 | −9.93% | 7.200 | −4.95% | 7.011 | −7.45% |
| Derivative-2-Cl-7 | 7.125 | −5.94% | 7.181 | −5.20% | 7.153 | −5.57% |
| Derivative-2-Cl-8 | 7.076 | −6.59% | 7.119 | −6.02% | 7.097 | −6.31% |
| Derivative-2-Cl-9 | 7.012 | −7.43% | 7.100 | −6.27% | 7.056 | −6.85% |
| Derivative-2-Cl-10 | 7.027 | −7.23% | 7.024 | −7.27% | 7.025 | −7.26% |
| Derivative-3 | 7.322 | |||||
| Derivative-3-Cl-1 | 7.396 | 1.01% | 7.951 | 8.59% | 7.674 | 4.81% |
| Derivative-3-Cl-2 | 7.493 | 2.34% | 7.811 | 6.68% | 7.652 | 4.51% |
| Derivative-3-Cl-3 | 7.578 | 3.50% | 7.683 | 4.93% | 7.630 | 4.21% |
| Derivative-3-Cl-4 | 7.162 | −2.19% | 7.466 | 1.97% | 7.314 | −0.11% |
| Derivative-3-Cl-5 | 6.506 | −11.14% | 6.524 | −10.90% | 6.515 | −11.02% |
| Derivative-3-Cl-6 | 6.815 | −6.92% | 7.227 | −1.30% | 7.021 | −4.11% |
| Derivative-3-Cl-7 | 6.823 | −6.82% | 7.200 | −1.67% | 7.011 | −4.25% |
| Derivative-3-Cl-8 | 7.125 | −2.69% | 7.181 | −1.93% | 7.153 | −2.31% |
| Derivative-3-Cl-9 | 7.076 | −3.36% | 7.119 | −2.77% | 7.097 | −3.07% |
| Derivative-3-Cl-10 | 7.012 | −4.23% | 7.100 | −3.03% | 7.056 | −3.63% |
| Derivative-3-Cl-11 | 7.027 | −4.03% | 7.024 | −4.07% | 7.025 | −4.06% |
* H-QSAR model chosen Pred. AVG as the final prediction value.